Your shopping cart is currently empty

Dihydro-5-azacytidine (DHAC) is an active nucleoside analog with anti-leukemic activity that inhibits cell growth and induces DNA hypomethylation.Dihydro-5-azacytidine is used in the study of leukemia and tumors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | Inquiry | Inquiry |
| Description | Dihydro-5-azacytidine (DHAC) is an active nucleoside analog with anti-leukemic activity that inhibits cell growth and induces DNA hypomethylation.Dihydro-5-azacytidine is used in the study of leukemia and tumors. |
| In vitro | As a nucleoside analogue, Dihydro-5-azacytidine (DHAC) competes with cytidine triphosphate for incorporation into RNA, resulting in ribosomal degradation and defective protein synthesis [1]. |
| In vivo | In tumor-bearing mice (injected with L1210/0 cells), receiving an LD 10 dose of Dihydro-5-azacytidine (DHAC; 1500 mg/kg) results in a peak plasma concentration of 317 μM, with biexponential elimination characterized by a half-life (t 1/2) of 1.03 hours (α phase) and 5 hours (β phase)[2]. |
| Synonyms | NSC264880, DHAC, 5,6-Dihydro-5-azacytidine |
| Molecular Weight | 246.22 |
| Formula | C8H14N4O5 |
| Cas No. | 62488-57-7 |
| Smiles | O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C(=O)N=C(N)NC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.